December 14-16, 2020
★ VIRTUAL EVENT
Delivered in Eastern Standard Time (EST)
Join us at
Antibody Engineering & Therapeutics!
Get 10% off registration when you use code 20AET33
|
Molecular Devices
Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.
December 14-16, 2020|★ VIRTUAL EVENT, Delivered in Eastern Standard Time (EST)
THE #1 ANTIBODY ENGINEERING CONFERENCE FOR ACCELERATING NEXT GENERATION ANTIBODIES TO COMMERCIAL SUCCESS
Find the latest science, technology and partners in antibody engineering, immunobiology and next generation binders
2020 CONFIRMED KEYNOTE SPEAKERS
TO INSPIRE YOUR RESEARCH AND DEVELOPMENT EFFORTS
2020 CONFERENCE SESSION THEMES INCLUDE:
- Antibody Selection and Screening in Early Discovery
- Novel Non-cancer Targets for Therapeutic Antibodies
- Transforming Therapeutic Targets
- Developments in ADC Technology
- Inducible Activation of Antibodies to Enhance Therapeutic Index
- Bispecific T cell Engagers
- Novel Insights into Immunoglobulin Structures (i.e. Fabs, Fc, Antibody Oligomers and Complexes)
- Responding to the COVID-19 Pandemic with Antibodies, Small Molecule Drugs and Vaccines
- Sourcing Disease-specific Human Antibodies from Patient Repertoires
- Computational Modeling of Antibody-Antigen Interactions
- Antibody Binding Sites as Therapeutics: scFv, VHH, VNAR and Beyond
- FcR and Antibody Effector Functions
- Immune Oncology Antibodies
- Antibody Affinity Maturation and Developability Improvement for Lead Optimization
- Engineering Chimeric Antigen Receptors, T cell Receptors and Cytokines
#ANTIBODYENG
